Vasoactin Plus is indicated for the management of certain cerebrovascular disorders and associated conditions. The primary therapeutic use of the combination is to address neurological deficits that may follow specific cerebral events.

Quick Facts

• Targeted Conditions: Neurological deficits associated with cerebrovascular events.
• Primary Benefits: Supports management of cerebral circulatory deficiencies and secondary neurological complications.
• Use in Specific Hemorrhage: Used to reduce the incidence and severity of ischemic deficits following a type of intracranial bleeding.

This medication is frequently utilized for the improvement of neurological outcome following a subarachnoid hemorrhage (SAH) caused by a ruptured intracranial aneurysm. The inclusion of one component, Nimodipine, is utilized for its role in reducing the incidence and severity of resulting brain damage, which is a major complication of this type of bleeding. The dual component nature of Vasoactin Plus offers a comprehensive approach to support cerebral function and neuroprotection in affected patients.

Regulatory References

1. NIH MedlinePlus guidance

Who can and cannot use Vasoactin Plus?

---

The eligibility profile for this medicine is established for use in adult patients (18 years and older).

Populations for whom use is contraindicated

Use is contraindicated in patients with a known hypersensitivity to the formulation components. A major non-eligibility rule is for patients taking strong CYP3A4 inhibitors (such as certain azole antimycotics or HIV protease inhibitors), as this combined use carries an official risk of severe hypotension.

Age and Condition-specific Eligibility

The safety and effectiveness of the medicine have not been established in the pediatric population (under 18). Older adults require caution because age-related decreases in organ function are more frequent in this group. Patients with impaired hepatic function, such as cirrhosis, must be closely monitored and may require a formal dose adjustment. Use also requires caution in patients with severe hypotension.

Pregnancy and Lactation Status

Use during pregnancy is restricted (Pregnancy Category C) and permitted only if the potential benefit justifies the potential risk to the fetus. Use is not recommended for lactating mothers.

---

Connection to the overall eligibility profile The official regulatory profile establishes absolute prohibitions (contraindications) for hypersensitivity and certain concomitant medication use. Eligibility is further defined by explicit warnings that mandate caution, dose reduction, or non-recommendation based on the patient's hepatic function and specific life stages, such as those under 18 or those who are pregnant or nursing.

The interaction profile for Vasoactin Plus is based on the official regulatory documentation for its two components, Nimodipine and Citicoline. The most significant interactions involve the Nimodipine component and the enzyme CYP3A4, which is responsible for its metabolism.

Interactions Affecting Drug Exposure

Co-administration with Strong CYP3A4 Inhibitors (e.g., certain azole antimycotics, macrolide antibiotics, and HIV protease inhibitors) should generally be avoided. These substances are documented to significantly increase Nimodipine plasma concentration. Conversely, co-administration with Strong CYP3A4 Inducers (e.g., Rifampin, Phenytoin, or the herbal product St John's wort) is also generally avoided because they reduce Nimodipine exposure. Specific inhibitors like Cimetidine are documented to increase Nimodipine plasma concentrations by inhibiting hepatic CYP P-450. Furthermore, the consumption of Grapefruit or Grapefruit Juice is officially documented to increase plasma concentrations and should be avoided.

Pharmacodynamic Interactions and Formal Restrictions

The Nimodipine component may intensify the blood pressure lowering effect when co-administered with other antihypertensive drugs. For the Citicoline component, its use is formally prohibited with Meclofenoxate (Clophenoxate), as written in official documentation. Citicoline is also documented to potentiate the effects of L-dopa (Levodopa). Special attention is noted in regulatory documents for patients with impaired hepatic function (such as cirrhosis), as decreased metabolism increases the risk of high Nimodipine exposure.

Modulation of Receptor-Mediated Signaling

Vasoactin Plus acts within domains involving receptor- or enzyme-mediated signaling by initiating or suppressing specific signaling sequences. This mechanism modifies early molecular steps that shape systemic physiological outcomes, ultimately contributes to the modulation of heightened physiological activity.

---

Regulation of Dysregulated Pathways

The drug engages mechanisms that regulate overactive or dysregulated processes and is applied in contexts involving rapid modulation of physiological responses. It supports the regulation of processes driven by distinct signaling patterns, which attenuates the effect of elevated mediator concentrations within targeted pathways.

---

Influence on Systemic Physiological Adjustments

Vasoactin Plus modulates key pathways associated with heightened physiological responses and is relevant in systems where targeted pathway adjustment is required. By engaging mechanisms that influence feedback regulation within pathways, the drug results in downstream physiological adjustments reflecting receptor engagement.

How to Use Vasoactin Plus

The administration of Vasoactin Plus, a fixed-dose combination of Citicoline and Nimodipine, is based on established parameters for its components, particularly concerning its use for acute cerebrovascular events.

---

Administration Scope

Usage Parameter	Parameters
Route of Administration	The medication is used for Oral administration (tablets, capsules, or solution) and via Intravenous (IV) infusion.
Standard Nimodipine Dose	This component is administered at a standard dose of 60 milligrams (mg).
Dosing Frequency	The Nimodipine component is administered at a frequency of every four hours (q4h) for the acute course.
Timing Relative to Meals	Oral doses of the Nimodipine component are taken on an empty stomach, specifically one hour before or two hours after eating. Consumption of grapefruit or grapefruit juice is prohibited.

---

Procedural and Duration Constraints

The administration involves a time-sensitive, short-term course of therapy. Treatment for the acute indication is initiated within 96 hours following the onset of the cerebrovascular event and continued for a total duration of 21 consecutive days.

When swallowing is compromised, the oral form's contents may be prepared and administered via a nasogastric tube; however, it is specified that the contents of the oral form must not be administered intravenously. For patients with hepatic impairment, the standard 60 mg dose of the Nimodipine component involves a dose reduction to 30 mg every four hours.

Research evidence / Overview of Studies for Vasoactin Plus

Evidence for use in Aneurysmal Subarachnoid Hemorrhage (aSAH)

The research explored the use of one of the medication’s core components, Nimodipine, in study cohorts involving adult patients following a type of bleeding in the brain known as aneurysmal subarachnoid hemorrhage (aSAH). The available evidence is based on multiple large Randomized Controlled Trials (RCTs) and Systematic Reviews that examined functional outcomes and the incidence of secondary complications, such as delayed ischemic neurological deficits (DIND). Studies reported measurements related to the incidence of delayed ischemic neurological deficits and outcomes related to neurological function at follow-up assessments (e.g., 3-6 months). Research has also explored the combination of neuroprotective agents, like Citicoline, with this component in animal models, noting the patterns of response observed in preclinical studies.

Evidence for use in Acute Ischemic Stroke (AIS)

The research landscape for Vasoactin Plus in acute ischemic stroke (AIS) is primarily built upon preclinical studies using animal models of stroke, where the combination was observed in studies evaluating changes in tissue damage. Human clinical trials have evaluated the Citicoline component alone in adult patients. In preclinical settings, studies of the combination described measurements of reduced tissue damage in animal models. However, human trials of the single neuroprotective component provided inconsistent results regarding sustained functional outcomes. Data suggest the Nimodipine component, when studied alone for AIS, does not appear to contribute meaningfully to functional outcomes in human clinical trials for acute ischemic stroke.

Evidence Gaps and Areas of Uncertainty

Evidence quality varies across studies, and significant research limitations exist, particularly for the fixed-dose combination. Comparative evidence is lacking for the specific Vasoactin Plus combination drug against single-agent treatment or other standard care protocols in large, modern RCTs. As a result, the full extent of the patterns observed when combining these two agents in clinical settings is not fully established. Furthermore, follow-up durations were limited in many pivotal trials, and there is limited information for long-term outcomes or durability beyond the six-month mark.

Key Studies & References

1. Clinical effectiveness of nimodipine for the prevention of poor outcome after aneurysmal subarachnoid hemorrhage: A systematic review and meta-analysis
2. Meta-analysis of the effectiveness and safety of prophylactic use of nimodipine in patients with an aneurysmal subarachnoid haemorrhage
3. Nimodipine - StatPearls [Internet] (for general indication and mechanism context)

Common questions about Vasoactin Plus (FAQ)

---

Q: Is Vasoactin Plus a blood pressure medicine?

A: Vasoactin Plus is officially intended to help manage neurological outcomes following specific cerebrovascular events. While one component is a Calcium Channel Blocker, a class known for affecting blood pressure, its primary purpose in this context is selective action on the cerebral vasculature. Regulatory documents indicate that this medication may intensify the blood pressure-lowering effect if taken alongside other antihypertensive compounds.

---

Q: Can Vasoactin Plus affect sleep patterns?

A: Official information about the drug’s components indicates documented effects on the nervous system, which is the system that controls sleep and wakefulness. Adverse reaction listings often include general central nervous system (CNS) effects that may influence sleep.

---

Q: Can Vasoactin Plus affect results on a routine blood test?

A: Yes, official safety information mentions that adverse reactions can include a decrease in platelet counts (thrombocytopenia) and changes in elevated liver enzymes. These effects are reported and may be detectable on routine blood work.

---

Q: Why is the 'Plus' added to the name Vasoactin Plus?

A: The 'Plus' is used in the name to signify that the product is a fixed-dose combination drug containing two different active ingredients: Nimodipine and Citicoline. This naming convention is used to distinguish the combination product from a single-agent formulation.

---

Q: Is a headache a common side effect of Vasoactin Plus?

A: Yes, regulatory documents list headache as a Common side effect. This classification means it is officially reported to occur in more than 1 out of 100 people using the medicine.

---

Q: Is fatigue a documented side effect of Vasoactin Plus?

A: Yes, adverse reaction listings for the drug’s components have documented effects such as asthenia (a medical term for physical weakness or loss of energy) and fatigue. These are reported in official safety information.

---

Q: Is it normal to feel a bit light-headed when first starting Vasoactin Plus?

A: Decreased blood pressure (hypotension) is listed as a Very Common side effect in official safety information. Feeling light-headed or dizzy is a documented symptom related to the decrease in blood pressure described in the product's official safety documents.

---

Q: Can Vasoactin Plus affect a person's mood or energy level?

A: Adverse reactions documented in official sources include general effects on the nervous system, such as headache and dizziness. Any medication that affects the nervous system may, in some people, influence their mood or energy levels.

---

Q: Do any official documents mention Vasoactin Plus being appropriate for children?

A: Official regulatory documents clearly state that the safety and effectiveness of this medicine have not been established in the pediatric population (patients under 18 years of age).

---

Q: Do regulatory agencies classify Vasoactin Plus as low or high risk?

A: Regulatory agencies highlight a critical safety restriction: the contents of the oral form must never be administered intravenously due to the documented risk of potentially fatal cardiovascular events, indicating the need for special attention to administration rules.

---

Q: What are the non-directive guidelines for using Vasoactin Plus?

A: Official information provides guidance including administering the drug only enterally (by mouth or tube), to take the oral dose on an empty stomach (one hour before or two hours after eating), and to avoid consuming grapefruit or grapefruit juice due to interaction concerns.

---

Q: What is the recommended period of use described in the official documents?

A: For its primary acute indication, the official treatment protocol defines a time-sensitive, short-term course of 21 consecutive days. This course must be initiated within 96 hours of the cerebrovascular event.

---

Q: Does Vasoactin Plus have a boxed warning?

A: Yes, one of the components (Nimodipine) is subject to an FDA Boxed Warning. This warning explicitly instructs that the contents of the oral capsules must never be administered intravenously due to the serious risk of adverse effects, including death.

---

Q: Is Vasoactin Plus meant to be taken for a long period of time?

A: The official regulatory protocol for the acute indication defines a time-sensitive, short-term course of therapy lasting 21 consecutive days. Official documents do not provide information defining the drug's intended use for long-term or chronic maintenance.

---

Q: What is the expected timeline for Vasoactin Plus's full benefit?

A: Clinical studies for one of the core components reported measurements related to neurological function at follow-up assessments. These assessments measured outcomes at time points such as 3 to 6 months after the initial event.

---

Q: Do studies support the use of Vasoactin Plus for managing its primary condition?

A: Evidence is primarily based on the core components. Research on Nimodipine supports its use in reducing specific complications after cerebrovascular events. Evidence for the specific fixed-dose combination is described as having varying quality and limitations, including a lack of comparative data.

---

Q: Can older adults typically use Vasoactin Plus?

A: The use of the medicine in older adults is established but requires caution according to official documents. This is because age-related decreases in organ function are more frequent in this population, and caution and close monitoring of blood pressure and pulse rate are required in this patient group.

---

Q: Is Vasoactin Plus a type of statin?

A: No. Vasoactin Plus is officially classified as a Nootropic Agent and Calcium Channel Blockers Combination. Statins belong to a different pharmacological class used primarily for lowering cholesterol.

---

Q: Can Vasoactin Plus be split or crushed?

A: Official administration instructions detail that if a patient cannot swallow the capsule, the oral form's contents may be prepared and administered via a nasogastric tube. This indicates that manipulating the contents is allowed under specific conditions.

---

Q: Are there specific symptoms that require immediate medical attention while on Vasoactin Plus?

A: Official warnings about the administration route emphasize that incorrect intravenous use has led to potentially fatal cardiovascular events, including severe hypotension and cardiac arrest. Any sign of severe, rapid cardiovascular change should be treated with extreme urgency.

Official Storage Requirements

Vasoactin Plus must be stored at Controlled Room Temperature, defined as 20 C to 25 C. The product requires protection from light and moisture and must remain in its original, tightly closed container until use. Storage must not exceed 30 C, and the medication must not be frozen or refrigerated. If using the intravenous solution, specific handling requires it must not come into contact with PVC materials. As a critical safety measure, the product must be kept out of the sight and reach of children at all times.

Disposal Instructions

To dispose of unused or expired Vasoactin Plus, the primary method is to return it to an authorized drug take-back program. If this option is unavailable, the medicine should be mixed with an undesirable substance (such as dirt or used coffee grounds) and placed in a sealed container before discarding it into the household trash. The medication must not be thrown into wastewater.